Evaluating the efficacy of Ivabradine in reducing the frequency of PAC , in patients with symptomatic frequent PACs

Evaluating the clinical efficacy of adding Ivabradine to the standard treatment in reducing the frequency of premature atrial complexes (PAC) in ECG holter comparing to the standard treatment , in patients with symptomatic frequent premature atrial complexes (PAC)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230618058519N1

Enrollment

100

Registered

2023-08-16

Start date

2023-07-06

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frequent premature atrial complex (PAC). Atrial premature depolarization

Interventions

Intervention 1: Intervention group: Patients in intervention group use Ivabradine 5mg twice daily for 2 weeks. All of the patients in both groups, receive metoprolol 25mg BID as the standard treatment

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patient in ages between 18-75 years. PAC frequency in ECG holter be between 5-10 % (average of 8%). Patients who have the ability to understand and sign the letter of satisfaction.

Exclusion criteria

Exclusion criteria: Patient have the history of using Ivabradine during last 2 months. Patients having cardiovascular disorders. Patients having congenital long QT or QT>500 msec at the beginning of study. using drugs with reducing heart rate effect, which have major interactions with Ivabradine. Patients whom are pregnant or lactating or tending to become pregnant. Patients suffering from advanced liver disease (class C of Child-Pugh score). Patient having the history of using Ivabradine, whom has had discontinued Ivabradine because of adverse effects. Patient having AF rhythm.

Design outcomes

Primary

Measure	Time frame
Frequency of PAC in 24 hours ECG holter. Timepoint: To understand the effect of Ivabradine on reducing the frequency of PAC, further holter will be done on 12th day of study for 24 hours. Method of measurement: ECG holter.	—

Secondary

Measure	Time frame
Rate of reduction in PAC frequency in ECG holter. Timepoint: To understand the effect of Ivabradine on reducing the frequency of PAC, further holter will be done on 12th day of study for 24 hours. Method of measurement: 24 hours ECG holter.;Symptoms of patients with symptomatic frequent PACs. Timepoint: To understand the effect of Ivabradine on reducing the frequency of PAC, further holter will be done on 12th day of study for 24 hours. Method of measurement: 24 hours ECG holter.	—

Measure

Time frame

Rate of reduction in PAC frequency in ECG holter. Timepoint: To understand the effect of Ivabradine on reducing the frequency of PAC, further holter will be done on 12th day of study for 24 hours. Method of measurement: 24 hours ECG holter.;Symptoms of patients with symptomatic frequent PACs. Timepoint: To understand the effect of Ivabradine on reducing the frequency of PAC, further holter will be done on 12th day of study for 24 hours. Method of measurement: 24 hours ECG holter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Layla Nematipour

Tehran heart center

l.nematipour@gmail.com+98 21 8802 9600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026